Stock Events

Stock Events

Esperion Therapeutics

$3.19

92

+$0.01+0.31% Monday 13:30

Statistics

Day High

3.19

Day Low

3.18

52W High

4.18

52W Low

1.21

Volume

59,090,465

Avg. Volume

14,520,293

Mkt Cap

822.04M

P/E Ratio

0

Dividend Yield

-

Dividend

-

Earnings

4AugExpected

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q1 2026

Q2 2026

-0.21

-0.14

-0.07

-0

Expected EPS

-0.001429

Actual EPS

N/A

Financials

-5.63%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

403.14MRevenue

-22.68MNet Income

Analyst Ratings

4.08Average Price Target

The highest estimate is 5.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.

Buy

0%

Hold

100%

Sell

0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen produces Repatha, a PCSK9 inhibitor that competes directly with Esperion's cholesterol-lowering drugs.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, in collaboration with Sanofi, markets Praluent, another PCSK9 inhibitor, directly competing in the cholesterol management market.

Sanofi, partnering with Regeneron, is involved in the marketing of Praluent, making it a direct competitor in the cholesterol-lowering space.

Merck & Co. offers cholesterol management drugs that, while not PCSK9 inhibitors, still compete in the broader market for cholesterol treatment solutions.

AstraZeneca provides Crestor, a statin, which is part of the broader cholesterol management market, competing for similar patient populations.

Pfizer is known for its Lipitor, one of the best-selling cholesterol-lowering drugs, competing in the same therapeutic area.

Novartis has a portfolio of cardiovascular drugs that, while not directly competing as PCSK9 inhibitors, still vie for market share in the broader cardiovascular treatment space.

AbbVie, through its acquisition of Allergan, has expanded its portfolio into cardiovascular diseases, indirectly competing with Esperion.

GlaxoSmithKline offers a range of cardiovascular drugs, competing in the broader market for heart disease treatments.

Eli Lilly and Company, while not a direct competitor in the PCSK9 space, has a growing interest in cardiovascular diseases, potentially competing for the same patient demographic.

About

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.

Show more...

CEO

Mr. Sheldon L. Koenig M.B.A.

Employees

294

Country

United States

ISIN

US29664W1053

Listings

0 Comments

Share your thoughts

FAQ

What is Esperion Therapeutics stock price today?▼

The current price of ESPR is $3.19 USD — it has increased by +0.31% in the past 24 hours. Watch Esperion Therapeutics stock price performance more closely on the chart.

What is Esperion Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Esperion Therapeutics stocks are traded under the ticker ESPR.

Is Esperion Therapeutics stock price growing?▼

ESPR stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Esperion Therapeutics has showed a +26.09% increase.

What is Esperion Therapeutics market cap?▼

Today Esperion Therapeutics has the market capitalization of 822.04M

What is Esperion Therapeutics revenue for the last year?▼

Esperion Therapeutics revenue for the last year amounts to 403.14M USD.

What is Esperion Therapeutics net income for the last year?▼

ESPR net income for the last year is -22.68M USD.

How many employees does Esperion Therapeutics have?▼

As of September 04, 2026, the company has 294 employees.

In which sector is Esperion Therapeutics located?▼

Esperion Therapeutics operates in the Health & Wellness sector.

When did Esperion Therapeutics complete a stock split?▼

The last stock split for Esperion Therapeutics was on June 11, 2013 with a ratio of 1:7.

Where is Esperion Therapeutics headquartered?▼

Esperion Therapeutics is headquartered in Ann Arbor, United States.